vTv Therapeutics Will Participate in INNODIA Symposium at the EASD 61st Annual Meeting
vTv Therapeutics Inc. - Class A (VTVT)
Last vtv therapeutics inc. - class a earnings: 7/31 04:30 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.vtvtherapeutics.com
Company Research
Source: GlobeNewswire
HIGH POINT, N.C., Sept. 15, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company, today announced that the company will present information on two of its investigational small molecules for type 1 diabetes (T1D) at the INNODIA Symposium during the European Association for the Study of Diabetes (EASD) 61st Annual Meeting. INNODIA is an international non-for-profit organization that aims to accelerate the development of therapies to prevent and cure T1D. Carmen Valcarce, Ph.D., Executive Vice President and Chief Scientific Officer of vTv Therapeutics, will present new preclinical data from independent, researcher-run studies of TTP-RA conducted by Professor Josephine Forbes, Ph.D. of the University of Queensland. TTP-RA is vTv’s oral RAGE (Receptor for Advanced Glycation End-products) antagonist, being evaluated in combination with an anti-CD3 antibody for the prevention of T1D. vTv is actively seeking strategic partnerships to advan
Show less
Read more
Impact Snapshot
Event Time:
VTVT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VTVT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VTVT alerts
High impacting vTv Therapeutics Inc. - Class A news events
Weekly update
A roundup of the hottest topics
VTVT
News
- vTv Therapeutics (NASDAQ:VTVT) had its "sell (d-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- vTv Therapeutics (NASDAQ:VTVT) had its "sell (d-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- vTv Therapeutics (NASDAQ:VTVT) was upgraded by analysts at BTIG Research to a "strong-buy" rating.MarketBeat
- vTv Therapeutics (NASDAQ:VTVT) is now covered by analysts at BTIG Research. They set a "buy" rating and a $40.00 price target on the stock.MarketBeat
- vTv Therapeutics (NASDAQ:VTVT) had its "sell (d-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
VTVT
Earnings
- 5/15/25 - Miss
VTVT
Sec Filings
- 11/25/25 - Form EFFECT
- 11/12/25 - Form SCHEDULE
- 11/6/25 - Form 10-Q
- VTVT's page on the SEC website